Acute Coronary Syndrome (ACS) is a critical and potentially life-threatening condition that encompasses a range of cardiovascular emergencies, including unstable angina and myocardial infarction (heart attack). ACS arises from the sudden reduction or blockage of blood flow to the heart muscle, often caused by the rupture of a plaque within a coronary artery. This disruption leads to the formation of blood clots, further compromising blood supply. The hallmark symptoms of ACS include chest pain or discomfort, shortness of breath, and sweating, requiring immediate medical attention. Rapid and accurate diagnosis is paramount, as timely intervention can mitigate damage to the heart muscle and improve patient outcomes. Treatment strategies for ACS may involve medications to alleviate symptoms, restore blood flow, and prevent future events, along with lifestyle modifications and cardiac rehabilitation. Ongoing research continues to refine our understanding of ACS, contributing to advancements in both diagnostic techniques and therapeutic interventions, with the ultimate goal of enhancing the prognosis and quality of life for individuals affected by this cardiovascular emergency.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India